
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
A hydrophilic topical cannabidiol formulation produced a sustained, largely local IOP reduction in DBA/2J mice with chronic dosing, adding a new wrinkle to one of glaucoma’s longest-running debates.
Cannabis has proven to be one of the most enduring and contentious topics in glaucoma management. Although states mention glaucoma as a qualifying diagnosis for medicinal marijuana and patients inquire about it, the clinical consensus has long been that cannabinoids are not a good fit for a condition that requires constant pressure control.2,3 According to a recent preclinical investigation that was published in the European Journal of Pharmacology, the delivery system rather than the molecule itself may have contributed to at least some of the issue.1
Researchers at Universidad Rey Juan Carlos in Madrid, Spain, evaluated a novel water-soluble topical CBD eye drop in DBA/2J mice, a spontaneous, age-dependent model of glaucoma that develops ocular hypertension, neuroinflammation, and progressive retinal ganglion cell loss. Outbred CD-1 mice, which do not develop spontaneous glaucoma, served as a non-glaucomatous comparator strain.1
Rethinking the formulation
CBD’s lipophilicity has historically limited its usefulness as an eye drop. As the authors note, the vast majority of a topically applied drug runs off the eye within seconds, and earlier cannabinoid work has produced contradictory results on IOP.1 A 2018 mouse study found that CBD increased IOP and blunted the pressure-lowering effect of THC,7 and a small sublingual study in patients with ocular hypertension or early open-angle glaucoma found that a 40-mg CBD dose produced a transient IOP rise.8
To get around solubility, the investigators used a hydrophilic formulation (Golar; Laboratoire Laredo) in which CBD at 9.54 mM (3 mg/mL) is coated in an aqueous dispersion containing low-molecular-weight sodium hyaluronate and poloxamer 407. A single 5-µL drop was applied to the right eye only, leaving the left eye untreated as an internal control.1
Treatment began at 33 weeks of age, once DBA/2J mice had established ocular hypertension (baseline IOP, 23.24 ± 0.87 mm Hg). After an acute dose, animals received 1 daily dose for 18 days, then 2 daily doses for 18 days, followed by a wear-off phase. Because general anesthesia alters IOP in mice, all rebound tonometry, von Frey corneal sensitivity testing, and Schirmer testing were performed in conscious animals by blinded investigators during a fixed morning window. In total, 51 male mice were studied.1
IOP response builds with chronic dosing
The authors describe an initial transient IOP rise, after which topical CBD progressively produced a significant and sustained reduction in IOP in the treated eyes of DBA/2J mice. The effect was most pronounced during the twice-daily phase, where both treatment and time-by-treatment interaction were statistically significant (P < .0001 for treatment). IOP gradually returned toward baseline after withdrawal.1
Notably, the hypotensive response held despite the age-related IOP climb characteristic of the strain, and the investigators reported no obvious tachyphylaxis—a key weakness of inhaled and systemic cannabinoids, whose IOP effect lasts only a few hours.1,2 In contralateral untreated eyes, IOP changes were smaller and inconsistent, which the authors interpret as evidence of a predominantly local effect.
A second target: the ocular surface
Perhaps the more clinically intriguing finding concerns corneal sensation. CBD increased the corneal touch threshold in DBA/2J mice, indicating reduced mechanical sensitivity, and the effect persisted through the wear-off phase. CD-1 mice showed no consistent change, which the authors suggest reflects preferential modulation of pathological rather than physiological nociception.1
Elisabeth M. Messmer, MD, FEBO, recently outlined in Ophthalmology Times, up to 59% of patients with glaucoma report dry eye symptoms, and adherence drops from 89% in patients without dry eye disease to 63% in those with it.6 An IOP-lowering agent that also soothes, rather than inflames, the ocular surface would address both problems at once. In the study, Schirmer test results and body weight were not meaningfully affected in either strain, suggesting reasonable ocular and systemic tolerability.1
Tempering expectations
The study has clear limits. It used only male mice, mechanistic analyses were outside its scope, and the authors themselves caution that responses may be strain-dependent and may not translate to humans. Four DBA/2J mice were lost during the study, including 1 that developed a severe corneal ulcer on treatment day 14, though the investigators attribute the losses to known strain vulnerabilities rather than the drug.1 The work was also funded by Laboratoire Laredo, which supplied the formulation.
Cannabinoid research in glaucoma has produced promising preclinical signals before, including cannabinol data covered on this site,5 without yet yielding a viable therapy. The American Academy of Ophthalmology continues to advise against cannabis products for glaucoma.3 Still, the idea that a better-engineered drop could deliver sustained, local pressure lowering alongside ocular surface benefits is a worthwhile reason to keep the question open—and a clear call for controlled human studies.4
References
Garcia MM, Paniagua NA, Rodríguez-Rivera C, et al. Chronic topical water-soluble cannabidiol formulation reduces intraocular pressure and corneal mechanical sensitivity in DBA/2J mice. Eur J Pharmacol. 2027;1040:179549. doi:10.1016/j.ejphar.2026.179549
Harrison L. Cannabis remains problematic for glaucoma. Ophthalmology Times. February 4, 2017. Accessed November 16, 2026.
https://www.ophthalmologytimes.com/view/cannabis-remains-problematic-glaucoma AAO: Don’t let patients self-medicate with marijuana to treat glaucoma. Ophthalmology Times. Accessed November 16, 2026.
https://www.ophthalmologytimes.com/view/aao-dont-let-patients-self-medicate-marijuana-treat-glaucoma Making the case for cannabis in treating glaucoma: mechanism of action. Ophthalmology Times. January 29, 2020. Accessed November 16, 2026.
https://www.ophthalmologytimes.com/view/making-case-cannabis-treating-glaucoma-mechanism-action Hnik P. Blog: Cannabinol, a rare cannabinoid, shows unique therapeutic potential in glaucoma. Ophthalmology Times. March 8, 2022. Accessed November 16, 2026.
https://www.ophthalmologytimes.com/view/blog-cannabinol-a-rare-cannabinoid-shows-unique-therapeutic-potential-in-glaucoma Messmer EM. From awareness to action: optimizing ocular surface health in glaucoma. Ophthalmology Times. January 31, 2026. Accessed November 16, 2026.
https://www.ophthalmologytimes.com/view/from-awareness-to-action-optimizing-ocular-surface-health-in-glaucoma Miller S, Daily L, Leishman E, et al. Δ9-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure. Invest Ophthalmol Vis Sci. 2018;59(15):5904-5911.
Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ. Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study. J Glaucoma. 2006;15(5):349-353.
Related to this article








